P. Nadella

417 total citations
13 papers, 292 citations indexed

About

P. Nadella is a scholar working on Oncology, Economics and Econometrics and Pathology and Forensic Medicine. According to data from OpenAlex, P. Nadella has authored 13 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Economics and Econometrics and 3 papers in Pathology and Forensic Medicine. Recurrent topics in P. Nadella's work include Health Systems, Economic Evaluations, Quality of Life (4 papers), Economic and Financial Impacts of Cancer (4 papers) and HER2/EGFR in Cancer Research (3 papers). P. Nadella is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (4 papers), Economic and Financial Impacts of Cancer (4 papers) and HER2/EGFR in Cancer Research (3 papers). P. Nadella collaborates with scholars based in United States and United Kingdom. P. Nadella's co-authors include Charles L. Shapiro, Donn C. Young, William E. Carson, Robin Parihar, Julie Dierksheide, William E. Burak, Cynthia M. Magro, Anne M. VanBuskirk, John L. Wilson and Miguel A. Villalona‐Calero and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

P. Nadella

13 papers receiving 286 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Nadella United States 8 195 82 55 41 37 13 292
Nancy Nixon Canada 10 233 1.2× 85 1.0× 43 0.8× 69 1.7× 45 1.2× 26 348
Zdeněk Mechl Hungary 10 159 0.8× 71 0.9× 34 0.6× 28 0.7× 13 0.4× 42 255
Lewis Au United Kingdom 11 267 1.4× 86 1.0× 52 0.9× 81 2.0× 37 1.0× 30 396
Julio E. Abugattas Peru 9 185 0.9× 47 0.6× 65 1.2× 21 0.5× 13 0.4× 22 283
Luis Z. Blanco United States 11 165 0.8× 63 0.8× 64 1.2× 74 1.8× 24 0.6× 32 358
Diego Enrico Argentina 8 136 0.7× 45 0.5× 20 0.4× 64 1.6× 29 0.8× 29 215
Laura Iezzi Italy 11 308 1.6× 84 1.0× 102 1.9× 79 1.9× 15 0.4× 21 411
Sherko Küemmel Germany 11 225 1.2× 29 0.4× 169 3.1× 88 2.1× 41 1.1× 42 310
Jason Cham United States 8 272 1.4× 173 2.1× 32 0.6× 84 2.0× 12 0.3× 20 355
Christophe Sajous France 9 129 0.7× 108 1.3× 57 1.0× 37 0.9× 18 0.5× 21 275

Countries citing papers authored by P. Nadella

Since Specialization
Citations

This map shows the geographic impact of P. Nadella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Nadella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Nadella more than expected).

Fields of papers citing papers by P. Nadella

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Nadella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Nadella. The network helps show where P. Nadella may publish in the future.

Co-authorship network of co-authors of P. Nadella

This figure shows the co-authorship network connecting the top 25 collaborators of P. Nadella. A scholar is included among the top collaborators of P. Nadella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Nadella. P. Nadella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Harvey, R. Donald, Taofeek K. Owonikoko, Carol M. Lewis, et al.. (2013). A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. British Journal of Cancer. 108(4). 762–765. 22 indexed citations
2.
Brufsky, Adam, Karen Hoelzer, Thaddeus Beck, et al.. (2011). A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer. Clinical Breast Cancer. 11(4). 211–220. 25 indexed citations
3.
Zimmerman, Brian, P. Nadella, Thomas J. Rosol, et al.. (2009). Expression of Tumor Invasion Factors Determines Systemic Engraftment and Induction of Humoral Hypercalcemia in a Mouse Model of Adult T-cell Leukemia. Veterinary Pathology. 46(5). 1003–1014. 14 indexed citations
4.
Mrózek, Ewa, Bhuvaneswari Ramaswamy, Donn C. Young, et al.. (2006). Phase II Study of Weekly Docetaxel and Capecitabine in Patients with Metastatic Breast Cancer. Clinical Breast Cancer. 7(2). 141–145. 12 indexed citations
5.
Eisenbeis, Charles F., Gregory B. Lesinski, Mirela Anghelina, et al.. (2005). Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12. Journal of Clinical Oncology. 23(34). 8835–8844. 19 indexed citations
6.
Parihar, Robin, P. Nadella, Julie Dierksheide, et al.. (2004). A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies. Clinical Cancer Research. 10(15). 5027–5037. 92 indexed citations
7.
Gillespie, Theresa, et al.. (2004). Improving clinical outcomes in elderly oncology patients. Journal of Clinical Oncology. 22(14_suppl). 6075–6075. 1 indexed citations
8.
Gillespie, Theresa, et al.. (2004). Improving clinical outcomes in elderly oncology patients. Journal of Clinical Oncology. 22(14_suppl). 6075–6075. 1 indexed citations
9.
Patterson, Helen, et al.. (2004). Compliance with guidelines for elderly patients undergoing cancer therapy. Journal of Clinical Oncology. 22(14_suppl). 6148–6148. 1 indexed citations
10.
Patterson, Helen, et al.. (2004). Compliance with guidelines for elderly patients undergoing cancer therapy. Journal of Clinical Oncology. 22(14_suppl). 6148–6148. 1 indexed citations
11.
Nadella, P., et al.. (2003). Older women with breast carcinoma are less likely to receive adjuvant chemotherapy. Cancer. 98(6). 1141–1149. 45 indexed citations
12.
Nadella, P., Charles L. Shapiro, Gregory A. Otterson, et al.. (2002). Pharmacobiologically Based Scheduling of Capecitabine and Docetaxel Results in Antitumor Activity in Resistant Human Malignancies. Journal of Clinical Oncology. 20(11). 2616–2623. 57 indexed citations
13.
Parihar, Robin, et al.. (2001). Herceptin and interleukin-12 combination therapy in patients with HER2/neu-overexpressing malignancies: a phase I trial. European Journal of Cancer. 37. S172–S172. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nancy Nixon Breakdown of academic impact, for papers by Zdeněk Mechl Breakdown of academic impact, for papers by Lewis Au Breakdown of academic impact, for papers by Julio E. Abugattas Breakdown of academic impact, for papers by Luis Z. Blanco Breakdown of academic impact, for papers by Diego Enrico Breakdown of academic impact, for papers by Laura Iezzi Breakdown of academic impact, for papers by Sherko Küemmel Breakdown of academic impact, for papers by Jason Cham Breakdown of academic impact, for papers by Christophe Sajous
Rankless by CCL
2026